Physician profile
Vicki J Lyons
NPI 1326013574
$3,260.92
in general payments reported to CMS, 2019-2025
24 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $650 · 2021: $437 · 2022: $666 · 2023: $246 · 2024: $499 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $856.02 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $529.67 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $397.48 | 2019-2025 | |
| Grifols USA, LLC | $317.29 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $167.28 | 2019-2025 | Dupixent |
| Kaleo, INC. | $156.66 | 2019-2024 | Auvi-Q |
| Xoran Technologies LLC | $105.10 | 2020 | |
| Novartis Pharmaceuticals Corporation | $76.77 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $76.73 | 2020-2022 | |
| Csl Behring | $76.64 | 2020-2023 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $72.54 | 2025 | Neffy |
| Genentech USA, INC. | $68.22 | 2022-2023 | Xolair |
| Amgen INC. | $60.21 | 2022-2025 | Tezspire |
| Optinose US, INC. | $57.96 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $55.88 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $31.37 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $25.79 | 2023 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $25.68 | 2025 | Cuvitru |
| Pfizer INC. | $20.34 | 2024 | |
| Pharming Healthcare, INC. | $19.11 | 2025 | Ruconest |
| Abbvie INC. | $18.01 | 2022 | |
| Octapharma USA, INC. | $17.52 | 2020 | |
| Lucid Diagnostics INC. | $15.30 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.